JP2022520060A5 - - Google Patents

Info

Publication number
JP2022520060A5
JP2022520060A5 JP2021546263A JP2021546263A JP2022520060A5 JP 2022520060 A5 JP2022520060 A5 JP 2022520060A5 JP 2021546263 A JP2021546263 A JP 2021546263A JP 2021546263 A JP2021546263 A JP 2021546263A JP 2022520060 A5 JP2022520060 A5 JP 2022520060A5
Authority
JP
Japan
Prior art keywords
seq
nos
liposome
liposome according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546263A
Other languages
English (en)
Japanese (ja)
Other versions
JP7541527B2 (ja
JP2022520060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017235 external-priority patent/WO2020163730A2/en
Publication of JP2022520060A publication Critical patent/JP2022520060A/ja
Publication of JP2022520060A5 publication Critical patent/JP2022520060A5/ja
Priority to JP2024136910A priority Critical patent/JP2024178161A/ja
Application granted granted Critical
Publication of JP7541527B2 publication Critical patent/JP7541527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546263A 2019-02-08 2020-02-07 リン酸化タウペプチドワクチンの安全な投与の方法 Active JP7541527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024136910A JP2024178161A (ja) 2019-02-08 2024-08-16 リン酸化タウペプチドワクチンの安全な投与の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802870P 2019-02-08 2019-02-08
US62/802,870 2019-02-08
PCT/US2020/017235 WO2020163730A2 (en) 2019-02-08 2020-02-07 Method of safe administration of phosphorylated tau peptide vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024136910A Division JP2024178161A (ja) 2019-02-08 2024-08-16 リン酸化タウペプチドワクチンの安全な投与の方法

Publications (3)

Publication Number Publication Date
JP2022520060A JP2022520060A (ja) 2022-03-28
JP2022520060A5 true JP2022520060A5 (cg-RX-API-DMAC7.html) 2023-02-15
JP7541527B2 JP7541527B2 (ja) 2024-08-28

Family

ID=69780323

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546263A Active JP7541527B2 (ja) 2019-02-08 2020-02-07 リン酸化タウペプチドワクチンの安全な投与の方法
JP2024136910A Pending JP2024178161A (ja) 2019-02-08 2024-08-16 リン酸化タウペプチドワクチンの安全な投与の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024136910A Pending JP2024178161A (ja) 2019-02-08 2024-08-16 リン酸化タウペプチドワクチンの安全な投与の方法

Country Status (17)

Country Link
US (3) US11684576B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920966A2 (cg-RX-API-DMAC7.html)
JP (2) JP7541527B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210125048A (cg-RX-API-DMAC7.html)
CN (1) CN113710269A (cg-RX-API-DMAC7.html)
AU (1) AU2020219804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129252A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192203A1 (cg-RX-API-DMAC7.html)
IL (1) IL285163B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210211A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009508A (cg-RX-API-DMAC7.html)
MY (1) MY206596A (cg-RX-API-DMAC7.html)
PH (1) PH12021551876A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108312PA (cg-RX-API-DMAC7.html)
TW (1) TWI868106B (cg-RX-API-DMAC7.html)
WO (1) WO2020163730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN114728169A (zh) * 2019-09-23 2022-07-08 麦考瑞大学 tau蛋白病的治疗
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
US20250134991A1 (en) * 2021-08-20 2025-05-01 Thomas Jefferson University Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
EA003739B1 (ru) 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
KR100994748B1 (ko) * 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2005058137A2 (en) 2003-12-12 2005-06-30 University Of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006121656A2 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
MX2011009654A (es) 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第13族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第13族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP4657376A3 (en) 2015-08-14 2026-03-04 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.

Similar Documents

Publication Publication Date Title
TWI868106B (zh) 安全投予磷酸化Tau胜肽疫苗的方法
CN102333538B (zh) 免疫刺激性寡核苷酸
US20040038922A1 (en) Vaccine composition
US20030125292A1 (en) Mucoscal vaccine and methods for using the same
AU2002340662A1 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
EP2698164B1 (en) Dna vaccine
Kim et al. Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA
US20250170236A1 (en) A novel cationic adjuvant composition
JP2024532787A5 (cg-RX-API-DMAC7.html)
EP1505942B1 (en) Pathogen vaccines and methods for using the same
US20250134973A1 (en) Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
EA045311B1 (ru) Способ безопасного введения вакцины фосфорилированного пептида tau
EA051841B1 (ru) Липосомы, содержащие фосфорилированные тау-пептиды, для индукции стойких иммунных ответов
RU2025121157A (ru) Липосомальная конструкция
CN118159289A (zh) 用于诱导持续免疫反应的含有磷酸化Tau肽的脂质体
HK1194987B (en) Dna vaccine
HK1194987A (en) Dna vaccine